89bio
ETNB
ETNB was delisted on the 29th of October, 2025.
30 hedge funds and large institutions have $270M invested in 89bio in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
1.87% more ownership
Funds ownership: 75.72% → 77.59% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $275M → $270M (-$4.36M)
12% less funds holding
Funds holding: 34 → 30 (-4)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$5.29M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.69M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$1.28M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.2M |
| 5 |
BlackRock
New York
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.14M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$766K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$705K |
| 4 |
Goldman Sachs
New York
|
-$600K |
| 5 |
Morgan Stanley
New York
|
-$555K |
ETNB Hedge Fund Activity: Q1 2020 in Review
30 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q1 2020, worth a combined $270M — down 1.6% from $275M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ETNB and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 15 added.
The largest buyer was JP Morgan Chase, adding an estimated $5.29M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $3.14M sold.
- 30 institutional investors held 89bio (ETNB) as of Q1 2020, down from 34 in Q4 2019.
- Funds reported $270M of 89bio stock for Q1 2020, down 1.6% quarter-over-quarter.
- 4 funds opened new 89bio positions in Q1 2020 and 6 closed out, a net change of -2 holders.
- The largest 89bio buyer in Q1 2020 was JP Morgan Chase, an estimated $5.29M added.
- The largest 89bio seller in Q1 2020 was Alyeska Investment Group, an estimated $3.14M sold.
Based on aggregated 13F filings for Q1 2020.